PMID: 8584685Oct 1, 1995Paper

Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats

Progress in Neuro-psychopharmacology & Biological Psychiatry
Y OhnoM Nakamura

Abstract

1. Receptor binding and behavioral studies were performed to compare the effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, and with haloperidol (HAL) on dopamine and 5-HT receptors in rats. 2. SM-9018 treatment (10 mg/kg/day p.o.) for 2 weeks did not significantly change the density (Bmax) of striatal D2 receptors or the incidence of stereotyped behavior induced by apomorphine (APO). By contrast, HAL treatment (3 mg/kg/day p.o., for 2 weeks) significantly increased the D2 receptor density by about 55% and markedly enhanced the behavioral response to APO. 3. The density of 5-HT2 receptors in the cerebral cortex was significantly reduced (about 20%) by SM-9018 treatment without being affected by HAL. However, the hyperthermic response of rats to p-chloroamphetamine (p-CAMP, a putative 5-HT releaser) was unaltered by either treatment. 4. Neither SM-9018 nor HAL treatment changed the density of 5-HT1A receptors in the hippocampus. 5. These findings suggest that SM-9018 is weaker than HAL in inducing up-regulation and supersensitivity of the striatal D2 receptors after the subchronic treatment.

References

Jan 1, 1979·International Review of Neurobiology·R J Baldessarini, D Tarsy
Jun 19, 1991·European Journal of Pharmacology·B L Roth, R D Ciaranello
Dec 1, 1990·Japanese Journal of Pharmacology·T KatoM Nakamura
Jan 28, 1987·European Journal of Pharmacology·P JohanssonG Ellison
Jan 1, 1985·Psychopharmacology·D L CeulemansP A Janssen
Jan 1, 1972·Journal of Neural Transmission·H L Klawans, R Rubovits
Aug 1, 1980·The American Journal of Psychiatry·H L KlawansS Perlik
Dec 1, 1980·The Australian and New Zealand Journal of Psychiatry·G F Johnson
Jan 1, 1993·Psychopharmacology·J M GoldsteinJ B Malick
Aug 1, 1993·Japanese Journal of Pharmacology·Y MaruokaM Nakamura
Jan 1, 1993·Schizophrenia Bulletin·D V Jeste, M P Caligiuri
Sep 30, 1993·Nature·P SeemanH H Van Tol

❮ Previous
Next ❯

Citations

Oct 6, 1997·Biological Psychiatry·E V Gurevich, J N Joyce
Mar 26, 2003·Life Sciences·Dirk Van OekelenJosée E Leysen
Aug 22, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasElias Tzavellas
Jul 1, 1997·Expert Opinion on Investigational Drugs·G P Reynolds

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here